



Company Overview

Heat Biologics is a biopharmaceutical company that develops immunotherapies with the goal of activating a patient's immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot," and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.

Heat Biologics Provides Third Quarter 2020 Business Update

Nov 9 2020, 7:00 AM EST

Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator

Oct 7 2020, 7:30 AM EDT

Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th

Sep 9 2020, 7:30 AM EDT

Stock Overview

Symbol	HTBX
Exchange	Nasdaq
Market Cap	175.83m
Last Price	\$1.10
52-Week	\$0.195 - \$4.30

11/25/2020 04:00 PM EST

Investor Relations

investorrelations@heatbio.com

Management Team

Jeffrey Wolf

Founder, Chairman and CEO

Jeff Hutchins, Ph.D.

Chief Scientific and Operating Officer

George Peoples, M.D., FACS

Chief Medical Advisor

Guillermo (Bill) Arana, MS

Executive Director, Clinical Development

William L. Ostrander

Vice President of Finance and Secretary

Gary Vinson

Vice President, Chemistry and Manufacturing Controls (CMC)

Cheni Kwok, Ph.D., CLP

Senior Business Development Advisor

Matthew M. Seavey, Ph.D.

Executive Director of Research

Heat Biologics, Inc.

627 Davis Drive
Suite 400
Morrisville, NC 27560

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.